iPSC-Derived Dopaminergic Transplants Demonstrate Safety and Motor Improvement in Parkinson’s Disease.

Phase I/II trial published in Nature shows biologic activity and clinical benefit without serious adverse events.

TribeMD

TribeMD

4 min read

August 5, 2025

Carregando conteúdo…
Psychiatry

Sources

  • Doi D, Mori E, Itakura G, et al. Allogeneic transplantation of iPSC-derived dopaminergic progenitors in Parkinson’s disease: a phase I/II clinical trial. Nature. 2025;623(8015):512–521. doi:10.1038/s41586-025-08700-0.

Highlights
TribeMD

Written by TribeMD